DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Relatlimab
Biological: Nivolumab

First Posted Date: 2018-03-20

Last Posted Date: 2025-03-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 714

Registration Number: NCT03470922

Locations: 🇨🇦
Local Institution - 0124, Halifax, Nova Scotia, Canada
🇨🇦
Local Institution - 0068, Ottawa, Ontario, Canada
🇨🇦
Local Institution - 0128, Toronto, Ontario, Canada

and more 124 locations

Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin

Completed

Conditions: Undifferentiated Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-03-15

Last Posted Date: 2022-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 82

Registration Number: NCT03466814

Locations: 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: Relatlimab
Biological: Nivolumab
Drug: BMS-986205
Biological: Ipilimumab

First Posted Date: 2018-03-08

Last Posted Date: 2025-04-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 229

Registration Number: NCT03459222

Locations: 🇦🇺
Local Institution - 0011, Nedlands, Western Australia, Australia
🇺🇸
Local Institution - 0003, Aurora, Colorado, United States
🇮🇹
Local Institution - 0023, Rome, Italy

and more 19 locations

A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2018-03-08

Last Posted Date: 2022-06-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 158

Registration Number: NCT03457792

Locations: 🇩🇪
Local Institution, Freiburg im Breisgau, Germany

Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer

Active, not recruiting

Conditions: Renal Cell Cancer
Kidney Cancer
Adenocarcinoma, Renal Cell
Renal Cell Carcinoma
Cancer of the Kidney
Adenocarcinoma Of Kidney

First Posted Date: 2018-03-06

Last Posted Date: 2023-07-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT03455452

Locations: 🇫🇷
Local Institution - 0001, Paris, France

Long Term Quality of Life in Melanoma Patients in Netherlands

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-03-01

Last Posted Date: 2020-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 89

Registration Number: NCT03450876

Locations: 🇳🇱
Local Institution, Amsterdam, Netherlands

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

Completed

Conditions: Melanoma

Interventions: Other: Non-interventional

First Posted Date: 2018-02-28

Last Posted Date: 2019-08-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 333

Registration Number: NCT03448497

Locations: 🇬🇧
Local Institution, Cambridge, Cambridgeshire, United Kingdom

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Phase 1

Completed

Conditions: Heart Failure With Reduced Ejection Fraction
Dilated Cardiomyopathy

Interventions: Drug: MYK-491
Drug: Placebo

First Posted Date: 2018-02-27

Last Posted Date: 2023-02-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT03447990

Locations: 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

and more 14 locations

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Phase 1

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Hepatic Cirrhosis
Liver Fibrosis
Nonalcoholic Steatohepatitis

Interventions: Drug: BMS-986036

First Posted Date: 2018-02-26

Last Posted Date: 2020-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT03445208

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Biological: BMS-986258
Biological: Nivolumab
Drug: rHuPH20

First Posted Date: 2018-02-26

Last Posted Date: 2025-01-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92

Registration Number: NCT03446040

Locations: 🇺🇸
Local Institution - 0012, Lebanon, New Hampshire, United States
🇺🇸
Local Institution - 0007, Aurora, Colorado, United States
🇺🇸
Local Institution - 0016, Cincinnati, Ohio, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy